The MYD88 gene, prevalent in B-cell lymphomas and primary CNS lymphomas, serves as a crucial adaptor protein in interleukin-1 (IL-1) and Toll-like receptors (TLRs) signaling pathways and in the activation of nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-kB), and Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathways [12-14]. The gene discussed is NFKB1; the disease is B-cell non-Hodgkin lymphoma.